- 116th Congress
- FY19 Recap
- FY20 Appropriations Process
- Looking Ahead
116th Congress

House
235 Democrats
197 Republicans
3 Vacancies

Senate
53 Republicans
45 Democrats
2 Independents
# House Leadership in the 116th Congress

<table>
<thead>
<tr>
<th>Leadership Position</th>
<th>Member</th>
</tr>
</thead>
<tbody>
<tr>
<td>Speaker of the House</td>
<td>Nancy Pelosi (D-CA)</td>
</tr>
<tr>
<td>House Majority Leader</td>
<td>Steny Hoyer (D-MD)</td>
</tr>
<tr>
<td>House Majority Whip</td>
<td>James Clyburn (D-SC)</td>
</tr>
<tr>
<td>House Minority Leader</td>
<td>Kevin McCarthy (R-CA)</td>
</tr>
<tr>
<td>House Minority Whip</td>
<td>Steve Scalise (R-LA)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Committee</th>
<th>Chair</th>
<th>Ranking Member</th>
</tr>
</thead>
<tbody>
<tr>
<td>House Appropriations</td>
<td>Nita Lowey (D-NY)</td>
<td>Kay Granger (R-TX)</td>
</tr>
<tr>
<td>House Appropriations Labor-HHS Subcommittee</td>
<td>Rosa DeLauro (D-CT)</td>
<td>Tom Cole (R-OK)</td>
</tr>
<tr>
<td>House Energy &amp; Commerce</td>
<td>Frank Pallone (D-NJ)</td>
<td>Greg Walden (R-OR)</td>
</tr>
<tr>
<td>House Energy &amp; Commerce Health Subcommittee</td>
<td>Anna Eshoo (D-CA)</td>
<td>Michael Burgess (R-TX)</td>
</tr>
</tbody>
</table>
Majority

Nita Lowey (NY)
Chair, Full Committee

Rosa DeLauro (CT)
Chair, L-HHS Subcommittee

Lucille Roybal-Allard (CA)

Barbara Lee (CA)

Mark Pocan (WI)

Katherine Clark (MA)

Lois Frankel (FL)
New to Approps and L-HHS

Cheri Bustos (IL)
New to Approps and L-HHS

Bonnie Watson Coleman (NJ)
New to Approps and L-HHS
Majority

Richard Shelby (AL)
Chair, Full Committee

Roy Blunt (MO)
Chair, L-HHS Subcommittee

Lamar Alexander (TN)

Lindsey Graham (SC)

Jerry Moran (KS)

Shelley Moore Capito (WV)

James Lankford (OK)

John Kennedy (LA)

Marco Rubio (FL)

Cindy Hyde-Smith (MS)
116th Congress - Leadership of NIH Authorizing Committees

House Energy & Commerce Committee & Health Subcommittee

- Frank Pallone (D-NJ)
  Chair, Full Committee

- Anna Eshoo (D-CA)
  Chair, Health Subcommittee

- Greg Walden (R-OR)
  Ranking Member, Full Committee

- Michael Burgess (R-TX)
  Ranking Member, Health Subcommittee

Senate Health, Education, Labor & Pensions Committee

- Lamar Alexander (R-TN)
  Chair

- Patty Murray (D-WA)
  Ranking Member
Labor-HHS FY19 Appropriation Enacted before October 1 – first time in 22 years

- Labor-H & Defense bills coupled
- $2B increase for NIH
- $74M increase for NCI
- $400M for Cancer Moonshot (Year 3 of 7)
Cancer Moonshot Funding Authorized
Under the 21st Century Cures Act (dollars in millions)
FY20 President’s Budget Request

- 14.6% for NCI
- +$50M Pediatric Initiative
NCI Appropriations FY 2015 - 2020 (dollars in millions)

21st Century Cures Act funding shown in orange.

Source: NCI Office of Budget and Finance
NCI/NIH BUDGET PROCESS FOR REGULAR APPROPRIATION

**STEP 1**
White House OMB coordinates with federal agencies to formulate the President’s budget proposal

**STEP 2**
Congressional appropriations committees consider President’s proposal & prepare legislation

**STEP 3**
Congress reconciles & finalizes appropriations legislation & sends to the President

**STEP 4**
President signs the appropriations bill into law making funds available for NIH & NCI

FY2020
Return of Budget Caps & the Debt Ceiling in FY20

- March 2019 – Debt ceiling reinstated
- October 2019 – Return of budget caps (defense and non-defense)
- We have been here before
Childhood Cancer STAR (Survivorship, Treatment, Access, Research) Act

- Signed into law in June 2018
- Includes provisions encouraging action from HHS, NCI, and CDC
- Required reporting

One Hundred Fifteenth Congress
of the
United States of America
AT THE SECOND SESSION
Began and held at the City of Washington on Wednesday, the third day of January, two thousand and eighteen

An Act
To maximize discovery, and accelerate development and availability, of promising childhood cancer treatments, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE; TABLE OF CONTENTS.
(a) SHORT TITLE.—This Act may be cited as the “Childhood Cancer Survivorship, Treatment, Access, and Research Act of 2018” or the “Childhood Cancer STAR Act”.
Includes three sections directed toward NIH/NCI (Secs. 101, 111/112, and 202)

- focus on new and continuing investments into childhood, adolescent, and young adult cancer survivorship research (Sec. 202), as well as biospecimen collection and resources (Sec. 101)

- provisions relating to ped-onc representation (Sec. 111/112) and childhood cancer reporting
Legislative Implementation

STAR (Survivorship, Treatment, Access, Research) Act

New Activities Underway as of March 2019 include:

▪ RFA, *Improving Outcomes for Pediatric, Adolescent and Young Adult Cancer Survivors*, posted last month, and aligns directly with the STAR Act. Receipt dates are March 15, 2019 and January 3, 2020.

▪ NCI is planning a meeting in May 2019 to discuss scientific challenges related to pediatric biospecimen collection. The meeting will include pediatric cancer researchers, biospecimen science experts, research organizations and advocates, and will inform implementation opportunities for the STAR Act’s biospecimen and biorepository provisions.
Questions?

mk.holohan@nih.gov
240-781-3410